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creatic surgery. These guidelines provide evidence-based recommendations
for the definition, diagnosis, and management of EPI after pancreatic surgery.
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E xocrine pancreatic insufficiency (EPI) is a common complicationafter pancreatic surgery. Depending on the underlying disease,
type of surgical procedure, extent of pancreatic resection, and
anatomical reconstruction, EPI may vary in frequency and severity.
Despite the large amount of information dealing with general post-
operative complications, there is a lack of well-designed studies
investigating EPI. This has led to a certain degree of confusion about
the frequency of EPI after surgery, its optimal methods of diagnosis
and when and how to treat these patients. The aim of these guidelines
is to provide evidence-based recommendations for the diagnosis and
treatment of EPI after pancreatic surgery.
METHODS
The Spanish Association of Pancreatology (AESPANC) led the
initiative and chose two coordinators (E. de-M. and L. S.) who
developed the methodology. Eighteen Spanish primary reviewers were
chosen, based on their expertise in pancreatic surgery, clinical pan-
creatology or nutrition (nine surgeons, eight gastroenterologists, and
one endocrinologist). A group of external expert referees, composed by
three pancreatic surgeons and three gastroenterologists, were invited to
participate in the project. These referees were selected among interna-
tionally renowned researchers in pancreatology. A draft of the ques-
tions to be addressed was proposed by the coordinators and discussed
by the whole team (via e-mail) finally resulting in 10 questions.
The coordinators assigned each question to two or three
primary reviewers based on their expertise. A working plan for
the systematic review was provided, inspired by the IAP/APA
evidence-based guidelines for the management of acute pancreatitis.1
All reviewers were asked to take a GRADE system tutorial (link on
UpToDate: http://www.uptodate.com/home/grading-tutorial).
The systematic research for suitable articles was performed in
the PubMed and Cochrane databases without language restriction. The
authors were provided with a search algorithm for each question (see
supplementary material 1, http://links.lww.com/SLA/B4). In addition,
studies fromthe citationsof the reviewed articlescouldalsobe included.
The inclusion criteria to select the articles were as follows:
observational studies, clinical trials, and meta-analysis/systematic
reviews relevant to the specific question. Studies published only as





2A table with a structured summary of the included studies
(authors, journal, date of publication, design, population, defi-
nition of outcome variable, results, and comments).2. An evidence-based statement to the study question.
The strength of the recommendation (1¼ strong, 2¼weak) and
quality of evidence (A¼ high, B¼moderate, C¼ low) according
to the GRADE guidelines as adapted for ‘‘UpToDate’’ (Table 1).
4. Remarks: a brief (up to 750 words) commentary explaining
current evidence to support the recommendation.
The external expert referees were asked to review the report of
primary reviewers; their task was to check that:1. There was no relevant study missing.opyright © 2016 Wolters Kluwer Health, Inc. Un
Included studies met the eligible criteria.
| www.annalsofsurgery.comau
pre3. There was no mistake in the report of the included studies.
4. The strength of recommendation was adequate according to the
retrieved evidence.
With the retrieved information by primary reviewers and exter-
nal expert referees, the coordinators wrote a first draft of the manu-
script. This draft was reviewed by the whole team and afterwards
shared electronically with the members of AESPANC. The members
of AESPANC voted on a five-point Likert scale (A: ‘‘definitely yes’’,
B: ‘‘probably yes’’, C: ‘‘no specific recommendation’’, D: ‘‘probably
no’’, and E: ‘‘definitely no’’) on the statements and their GRADE
score. It was defined that ‘‘strong agreement’’ would require at least
70% of votes to be either ‘‘definitely yes’’ or ‘‘probably yes’’. The
members of AESPANC also had the possibility of making suggestions
in open text for every question, aiming not to modify the statement but
to include clinically relevant remarks.
With the feedback from AESPANC members, the coordina-
tors wrote the second draft of the article that was shared again with
the primary reviewers and with the external expert referees for
suggestions and final approval.
RESULTS
Question 1
What Is the Definition of EPI After Pancreatic Surgery?
Statement. EPI after pancreatic surgery is defined as the
condition in which the amount of secreted pancreatic enzymes is
not enough to maintain a normal digestion because of modifications
of gastrointestinal anatomy together with functional changes caused
by underlying pancreatic disease, extent of pancreatic tissue
removed, reduced postprandial stimulation, and asynchrony between
gastric emptying of nutrients and pancreatic enzyme secretion.
Strength of the Recommendation and Quality of
Evidence: 1C. Strong Agreement (A: 87.5%; B: 12.5%)
Remarks. There is no widely accepted consensus definition of
EPI, and there are no studies aiming to validate different EPI defi-
nitions with outcome variables after pancreatic surgery. Published
studies addressing EPI after surgery have different definitions accord-
ing to the different pancreatic function test (PFT) used in each
particular study. From a pragmatic point of view, EPI may be defined
as the situation in which the disturbance of pancreatic function is
associated with the inability of the pancreas to perform normal
digestion.2 Thus, an abnormally high fecal fat excretion (FFE)
(>7 g/day) or a Coefficient of Fat Absorption (CFA)<93% (equivalent
to a FFE >7 g/day under a diet containing 100 g of fat/day) is
characteristically indicative of EPI in clinical practice2–4 and should
be considered as a gold standard. EPI after surgery may be secondary to
a reduced pancreatic secretion caused by the underlying pancreatic
disease,3,5 extent of pancreatic resection,6 reduced postprandial stimu-
lation,7,8 and gastrointestinal anatomical changes leading to an asyn-
chrony between gastric emptying of nutrients and enzyme secretion.9
Question 2
What Is the Frequency of EPI in Patients With Acute
Pancreatitis After Pancreatic Necrosectomy?
Statement. The frequency of EPI in patients with acute
pancreatitis after necrosectomy is variable because of significant
heterogeneity in the design and population of available studies
addressing this issue. Pancreatic function tends to improve and
consequently frequency of EPI diminishes over time after necrosec-
tomy. About a quarter of patients with acute necrotizing pancreatitisthorized reproduction of this article is prohibited.
sent EPI after pancreatic necrosectomy.
 2016 Wolters Kluwer Health, Inc. All rights reserved.
CE: A.G.; ANNSURG-D-16-00238; Total nos of Pages: 10;
ANNSURG-D-16-00238
TABLE 1. Grading Recommendations




risk and burdens, or vice
versa
Consistent evidence from well performed
randomized, controlled trials or
overwhelming evidence of some other
form. Further research is unlikely to
change our confidence in the estimate of
benefit and risk
Strong recommendations, can apply to
most patients in most circumstances
without reservation. Clinicians
should follow a strong
recommendation unless a clear and
compelling rationale for an





risk and burdens, or vice
versa
Evidence from randomized, controlled trials
with important limitations (inconsistent
results, methodologic flaws, indirect or
imprecise), or very strong evidence of
some other research design. Further
research (if performed) is likely to have an
impact on our confidence in the estimate of
benefit and risk and may change the
estimate
Strong recommendation and applies to
most patients. Clinicians should
follow a strong recommendation
unless a clear and compelling




Benefits appear to outweigh
risk and burdens, or vice
versa.
Evidence from observational studies,
unsystematic clinical experience, or from
randomized, controlled trials with serious
flaws. Any estimate of effect is uncertain
Strong recommendation, and applies to
most patients. Some of the evidence
base supporting the





with risks and burdens.
Consistent evidence from well performed
randomized, controlled trials or
overwhelming evidence of some other
form. Further research is unlikely to
change our confidence in the estimate of
benefit and risk
Weak recommendation, best action may
differ depending on circumstances





with risks and burdens,
some uncertainly in the
estimates of benefits,
risks, and burdens.¼
Evidence from randomized, controlled trials
with important limitations (inconsistent
results, methodologic flaws, indirect or
imprecise), or very strong evidence of
some other research design. Further
research (if performed) is likely to have an
impact on our confidence in the estimate of
benefit and risk and may change the
estimate
Weak recommendation, alternative
approaches likely to be better for




Uncertainty in the estimates
of benefits, risks, and
burdens; benefits may be
closely balanced with
risks and burdens
Evidence from observational studies,
unsystematic clinical experience, or from
randomized, controlled trials with serious
flaws. Any estimate of effect is uncertain
Very weak recommendation; other
alternatives may be equally
reasonable
From: http://www.uptodate.com/home/grading-guide.
Annals of Surgery  Volume XX, Number X, Month 2016 Guidelines for Exocrine Pancreatic InsufficiencyStrength of the Recommendation and Quality of
Evidence: 1C Strong Agreement (A: 45%; B: 55%)
Remarks. There is a great heterogeneity in the design of
studies addressing EPI after pancreatic necrosectomy. Some studies
used FFE to assess pancreatic function and define EPI as FFE >7 g/
24 h. Gupta et al10 reported increased FFE in six out of 21 patients
(28.6 %) at least 6 months after necrosectomy. Sabater et al11
compared exocrine pancreatic function in patients with severe biliary
AP with and without necrosectomy. Pancreatic function was assessed
by FFE, fecal chymotrypsin and secretin-cerulein test (SCT), 12
months after AP. Seven out of 12 patients with necrosectomy (58.3
%) had abnormal PFT, with steatorrhea in three patients (25 %).
Reddy et al12 reported increased FFE in eight out of 10 (80 %)
patients with necrosectomy, but no patient had symptoms of steator-
rhea or EPI. Tsiotos et al13 and Bavare et al14 defined EPI with FFE,
but it was only performed in patients with significant changes in
bowel habit; thus, the prevalence of EPI could be underestimated.
Angelini et al15 reported EPI (evaluated with SCT) in eight outCopyright © 2016 Wolters Kluwer Health, Inc. U
of 20 patients with necrosectomy (40 %) at 12 to 36 months and in 6.6
 2016 Wolters Kluwer Health, Inc. All rights reserved.% at 36 to 48 months after the onset of disease. Seligson et al16
detected EPI in 7/10 (70%) patients with Lundh Test.
Other studies are hampered by important biases: the presence
of acute and chronic pancreatitis17 or the inclusion of nonoperated
patients.18 Finally, in some studies, EPI was reported on the basis of
need for pancreatic enzymes or clinical symptoms of steatorrhea,
with figures between 2319 and 25%,20 respectively. In this regard, it is
noteworthy to highlight the results of the PANTHER trial from the
Dutch Pancreatitis Study group, in which the minimally invasive
step-up approach was significantly associated with a lower need for
pancreatic enzymes than in primary open necrosectomy (7 vs
33%).21
Question 3
What Is the Frequency of EPI in Patients with Chronic
Pancreatitis After Pancreatic Surgery?
Statement. The incidence of EPI in patients with chronicnauthorized reproduction of this article is prohibited.
pancreatitis after derivative surgery or hybrid procedures is the
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Sabater et al Annals of Surgery  Volume XX, Number X, Month 2016following: (i) after Partington-Rochelle procedure there are clinical
steatorrhea and/or other clinical symptoms in 0 to 32% of patients
and altered PFT in 80%; (ii) after Frey procedure there are clinical
steatorrhea and/or other clinical symptoms in 33% of patients and
altered PFT in 86%; (iii) after duodenum preserving pancreatic head
resection (DPPHR) there are clinical steatorrhea and/or other clinical
symptoms in 26 to 34% of patients and altered PFT in more than 80%
of patients.
The incidence of EPI after pancreatoduodenectomy (PD) for
chronic pancreatitis is high, within the range of 35 to 100%, most of
the studies showing >60%. The incidence of EPI after distal
pancreatectomy (DP) for chronic pancreatitis seems to be lower,
ranging from 27.5 to 63%.
As there is a high prevalence of EPI in chronic pancreatitis
patients, and few studies evaluate EPI before pancreatic surgery, the
specific contribution of the surgical procedure to EPI is difficult
to quantify.
Strength of the Recommendation and Quality of
Evidence: 1C Strong Agreement (A: 52.5%; B: 45%; C:
2.5%)
Remarks. The studies addressing EPI in patients with chronic
pancreatitis after derivative surgery or hybrid procedures can be
divided into five groups: articles comparing Partington-Rochelle
versus PD22–25; articles comparing Frey versus PD26–28; articles
comparing DPPHR versus PD29–36; articles comparing DPPHR
versus Frey procedure,37,38 and miscellaneous retrospective
series.39–41 According to these studies, (i) after Partington-Rochelle
procedure there are clinical steatorrhea and/or other clinical symp-
toms in 0 to 32% of patients and altered PFT in 80 %; (ii) after Frey
procedure there are clinical steatorrhea and/or other clinical symp-
toms in 33% of patients and altered PFT in 86%; and (iii) after
duodenum preserving pancreatic head resection (DPPHR) there are
clinical steatorrhea and/or other clinical symptoms in 26 to 34% of
patients and altered PFT in more than 80% of patients.
Regarding the frequency of EPI in patients with chronic
pancreatitis after resectional procedures (PD, DP), four prospective
RCT28,30,31,34 (two of them with long-term follow- up), two pro-
spective nonrandomized studies,26,29 two meta-analyses,32,35 and 10
retrospective studies22–24,27,33,40,42–45 were included. The incidence
of EPI after PD operation ranged from 35 to 100%. However, some
concerns can be raised as to the quality of these findings. First, EPI
was not the primary outcome in the majority of these studies, which
were mainly designed to compare different surgical techniques.
Furthermore, definition of EPI was not homogeneous and it seems
that clinical definition (expressed by questionnaire or need for
pancreatic enzymes) detected a generally lower number of patients
with EPI when compared with PFT. Second, in most nonrandomized
studies, Whipple’s operation was performed when pancreatic cancer
was suspected or pancreatic duct was not dilated, causing an import-
ant selection bias. Finally, preoperative assessment of EPI was
scarcely performed and high variability was reported among studies.
Except for one study,42 surgery always increased the incidence of
EPI. The two meta-analyses32,35 do not report any definition of EPI,
hence making interpretation difficult. The only study that seems to
avoid the previously mentioned biases is Izbicki’s RCT,46 whose
long-term results have been reported by Bachmann et al.28 This study
shows that the incidence of EPI is 93% with a 15-year follow up and
thus this value should be taken into account when predicting the
occurrence of EPI following PD for chronic pancreatitis. An import-
ant consideration regarding maldigestion after this operation is that,
in addition to the reduction of pancreatic tissue,6 PD alters theCopyright © 2016 Wolters Kluwer Health, Inc. Un
physiological mechanisms that regulate gastric emptying,
4 | www.annalsofsurgery.comstimulation of biliopancreatic secretions and mixing of the nutrient
particles with pancreatic enzymes because of the removal of struc-
tures that are necessary for normal digestion.9,47,48 This procedure
leads to an asynchrony between the gastric emptying of nutrients and
biliopancreatic secretion for the following reasons: (i) the loss of
antrofundic and duodenofundic reflexes that hinders the accommo-
dation of nutrients in the gastric cavity; (ii) the absence of neurally
mediated pancreatic stimulation; (iii) loss of food-grinding capacity
that results in large nutrient particles that cannot be adequately mixed
with biliary and pancreatic secretions and are therefore difficult to be
absorbed by the intestine; and (iv) the resection of duodenum which
avoids the release of cholecystokinin7,8 and consequently there is a
reduction of postprandial hormonal pancreatic stimulation.
Regarding DP, the incidence of EPI ranged from 27.5 to 63%.
As mentioned before, the definition of EPI and the scarce preoper-
ative assessment of pancreatic function can be considered
strong biases.
Question 4
What Is the Frequency of EPI in Patients With
Pancreatic Tumors After Resection (PD, DP)?
Statement. The incidence of EPI after PD for pancreatic
tumors is high, especially in patients undergoing PD caused by
malignancy, with a range of 64 and 100 %. The incidence of EPI
after DP is lower than after PD, within a range of 0 to 42%.
Strength of the Recommendation and Quality of
Evidence: 1C Strong Agreement (A: 67.5%; B: 32.5%)
Remarks. Information regarding the incidence of EPI in
patients with pancreatic tumors after resection is limited and there
is a lack of well-designed studies. Most available studies are retro-
spective and cross-sectional, limited by small sample size and single-
institution designs. They also include a heterogeneous patient popu-
lation with malignant and benign diseases. They include different
types of surgery: PD, DP, and atypical resections. In addition, most of
the reports include patients with and without chronic pancreatitis,
and have used different methods to assess the pancreatic exocrine
function. As mentioned before, maldigestion after PD has a complex
pathophysiology that involves other factors besides the removal of
pancreatic tissue (see questions 1 and 3).
Twenty-two studies have described the impairment of
exocrine function after pancreatic head resection;4–6,49–67 14 studies
included only patients who underwent PD,5,52,54,56–62,64–67 seven
studies included both PD and DP4,6,49,50,53,55,63 (central or total
pancreatectomy in three of them),50,53,55 and one study included
PD and total pancreatectomy.51 Fourteen studies included a hetero-
geneous patient population with malignant and benign diseases,6,50–
54,56–60,62–64 five studies included only patients with malignant
disease,4,5,49,61,66 and one study covered only benign tumors.55 There
was also one meta-analysis.68
Among the studies, seven different methods for the assessment
of EPI were applied (Table 2). As seen in this table, depending on the
method used to evaluate exocrine pancreatic function, results
vary considerably.
EPI rates varied widely from 24 to 100%. When only consid-
ering patients who underwent PD for malignant disease, EPI was
present in 64 to 100%.4,5,49,61 Five studies49,55,58,63,64 have evaluated
the preoperative and postoperative exocrine function. In the study by
Sikkens et al,49 EPI was present in 44.8% at the time of diagnosis of
pancreatic cancer increasing to 89% at the end of follow up. However,
follow up was limited to 6 months, the long-term course was notauthorized reproduction of this article is prohibited.
evaluated, and the study covered two types of surgery (DP and PD). In
 2016 Wolters Kluwer Health, Inc. All rights reserved.
CE: A.G.; ANNSURG-D-16-00238; Total nos of Pages: 10;
ANNSURG-D-16-00238
TABLE 2. Variability in Exocrine Pancreatic Insufficiency After
pancreatoduodenectomy According to the Different
Methods Used for Measuring EPI
Method EPI % References
Coefficient of fat absorption 55 4
Fecal fat excretion 87.5, 94 51, 62
13C-labelled mixed triglyceride
breath test
64, 62.3, 51 6, 54, 67
Urinary PABA excretion rate 33, 75 64, 65





Fecal chymotrypsin levels 24, 33 53, 55
Clinical steatorrhea 52.8, 52.4, 42, 64.5 52, 56, 59, 66
EPI indicates exocrine pancreatic insufficiency; PABA, para-aminobenzoic acid.
Annals of Surgery  Volume XX, Number X, Month 2016 Guidelines for Exocrine Pancreatic Insufficiencythe series by Falconi et al55 including 51 PD for benign tumors with
normal preoperative pancreatic exocrine function, EPI was observed in
33% at the end of follow up. Matsumoto and Traverso58 reported a
preoperative EPI rate of 33% (68% in pancreatic adenocarcinoma, and
46% in malignant vs 21% in benign disease), increasing to 73% after 1
year. In the study of Sato et al,63 the frequency of EPI increased from
44% in the preoperative period to 81% after pancreatic resection, but
follow up was limited to only 2 months. One study64 suggested that
postoperative impairment of pancreatic exocrine function was transi-
ent and reversible. EPI was present in 46% preoperatively, rose to 75%
at the short-term (within 2 months), and then decreased to 33% after 12
months, but this observation was based on data from only nine patients.
Furthermore, the study included a heterogeneous group of patients
with malignant and benign diseases.
Regarding DP, the incidence of EPI varied from 0 to 42%
depending on the method used to assess pancreatic exocrine function.
Similar biases can be observed in the studies evaluating this pro-
cedure as in PD and in fact most of the studies include both PD and
DP.4,6,49,50,53,55,63 One study69 showed that most patients who under-
went DP for benign or malignant pancreatic disease did not experi-
ence permanent postoperative EPI: all patients had normal exocrine
function after DP or extended DP at 24 months after surgery and in
the few cases where lower values were observed at 3 and 12 months
after DP, the effect was transient. In the study by Falconi et al55
including 50 left pancreatectomies for benign tumors with normal
preoperative fecal chymotrypsin levels, 18% presented EPI at the end
of follow up. Sato et al63 studied 12 patients who underwent DP for
benign or malignant tumors of the pancreas and did not observe a
significant decline in exocrine function after DP. Finally the meta-
analysis by Xu et al,68 showed an EPI rate of 10.8% in DP.
Question 5
What Is the Frequency of EPI in Patients With Central
Pancreatectomy? Statement
Central pancreatectomy is a conservative resectional pro-
cedure that is associated with low rates of EPI, approximately 10%.
Strength of the Recommendation and Quality of
Evidence: 1C Strong Agreement (A: 62.5%; B: 35%; D:
2.5%)
Remarks. Studies addressing EPI in central pancreatectomy
70,71Copyright © 2016 Wolters Kluwer Health, Inc. U
(CeP) have two important shortcomings: (i) with two exceptions
 2016 Wolters Kluwer Health, Inc. All rights reserved.the studies addressing EPI in CeP are retrospective and (ii) most
studies do not report PFT in patients with CeP and most reports of
EPI are based on clinical suspicion of steatorrhea and/or need for
enzymes. Furthermore, the only two prospective studies70,71 did not
perform PFT on patients with CeP.
Two studies reported FFE after CeP in patients with benign/
low grade pancreatic tumors resulting in only one among 28 (3.6%)
patients with EPI.72,73 In seven studies other PFT were performed
after CeP53,55,74–78 reporting a range of EPI between 055,74,76,77 and
21%.78 Studies reporting clinical EPI (steatorrhea and/or weight loss
and/or need for enzymes) describe a range between 0 79–88 and
43%.71 In a systematic review published in 2013, which included 21
studies, EPI (diagnosed either clinically or by means of diverse PFT)
was noted in 9.9% of the patients.89
Question 6
What Are the Clinical Consequences of EPI?
Statement. EPI after pancreatic surgery may be subclinical or
associated with symptoms secondary to the presence of undigested
food in the intestinal lumen (fatty diarrhea, flatulence, and dyspeptic
symptoms) and/or those associated with the loss of nutrients (weight
loss, fat-soluble vitamin deficit).
Strength of the Recommendation and Quality of
Evidence: 1C Strong Agreement (A: 77.5%; B: 17.5%;
C: 2.5%; D: 2.5%)
Remarks. EPI after pancreatic surgery is associated with
abnormal total energy absorption because of decreased digestion
of fat, proteins, and carbohydrates.90 EPI may be subclinical or
associated with two kinds of symptoms: those associated with the
presence of undigested food within the intestinal lumen (fatty
diarrhoea, flatulence, dyspeptic symptoms)91 and those associated
with the loss of nutrients (mainly weight loss and fat-soluble vitamin
deficit). The pancreas is involved in the digestion of proteins,
carbohydrates, fat, and other nutrients, but pancreatic lipase is so
essential for fat absorption that most of the clinical consequences of
EPI are related to fat maldigestion. The extent of malabsorption
depends on the original disease process and the type and extent of
surgical resection.92 The main clinical manifestation of fat malab-
sorption is steatorrhea typically reported as an increase in bowel
movements, particularly after fatty meals, with loose, greasy, foul-
smelling voluminous stools.47,93 Steatorrhea, however, may be not
present or present because of another cause. Postprandial abdominal
pain and abdominal bloating may also be associated with EPI.47
In patients with untreated EPI, potential additional compli-
cations such as weight loss, poor wound healing, vitamin
deficiencies, osteomalacia, osteoporosis, and low-trauma fractures,
electrolyte imbalance, increased adverse effects of oncological treat-
ments, and lethargy can theoretically appear. One study compared
pancreatic enzymes and placebo after surgery for chronic pancrea-
titis; four out of five patients receiving pancreatic enzymes gained
weight but none of those six patients receiving placebo did.90 Apart
from weight loss, there are no specific studies demonstrating a
different nutritional status in patients with or without EPI after
pancreatic surgery.4,49
Question 7
What Is the Optimal Method for the Diagnosis of EPI
After Pancreatic Surgery?
Statement. PFT are of limited clinical value after pancreaticnauthorized reproduction of this article is prohibited.
surgery as the prevalence of EPI is high and PFT are either difficult to
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evidence for EPI is needed, FFE may be considered as the gold
standard. Human elastase-1 (FE1) is easy to perform, has a high
sensitivity to detect steatorrhea but its specificity seems lower. The
13C-MTG may be an alternative method but further studies are
needed. The absence of clinical symptoms of steatorrhea is an
inaccurate method to rule out the existence of EPI.
Strength of the Recommendation and Quality of
Evidence: 2B Strong Agreement (A: 35%; B: 40%; C:
22.5%; E: 2.5%)
Remarks. Currently FFE/CFA may be considered as a gold
standard for EPI (see question 1). Unfortunately, this technique is
cumbersome to perform: it requires a specific diet with a given
amount of fat per day and stools from 3 days must be collected and
processed. For these reasons, it would be very useful to have simpler
PFTs like FE-1 and/or 13C-MTG but few studies have tried to
validate them for the diagnosis of steatorrhea by means of FFE or
CFA after pancreatic surgery.4,51 Halloran et al4 studied 40 operated
patients for pancreatic cancer (37 PD and only three left pancreatec-
tomies) by FE-1 and CFA. A comparison of FE-1 using a cut-off
point of 200 microg/g for EPI against CFA showed a diagnostic
accuracy of 70%, with a sensitivity of 91%, a specificity of 35%, a
positive predictive value of 70%, and a negative predictive value of
71% for FE-1. There was no clear association between CFA and FE-1
levels. Overall, this study suggests the limited accuracy of FE-1 to
diagnose EPI after pancreatic surgery. In another study Benini et al51
studied 40 operated patients (37 pylorus preserving PD, one Whipple
procedure, and two total pancreatectomies) and 42 nonoperated
patients with pancreatic diseases, and evaluated EPI by FE-1 com-
pared with FFE. Sensitivity and specificity of FE-1 in operated
patients to detect steatorrhea were as follows: 100% and 83.3%
for FE-1<200 mcg/g; 100% and 100% for FE-1<100 mcg/g and
61.8%, respectively, and 100% for FE-1<15 mcg/g. The cut-off for
FE-1 in the diagnosis of EPI was considerably higher in operated
compared with nonoperated patients. Another conclusion of this
study is that the relationship between both tests is not linear but
logarithmic. The rate of increase of 24 hours fecal fat output with
decreasing FE-1 levels is not constant but depends on FE-1 values,
with rates much higher when FE-1 values are low. The information
regarding the correlation between FE-1 and FFE in left pancreatec-
tomy is lacking. Nakamura et al94 investigated the usefulness of 13C-
MTG compared with FE-1 concentration, but they used clinicalCopyright © 2016 Wolters Kluwer Health, Inc. Un
steatorrhea as a gold standard. According to their results, the
TABLE 3. Advantages and Disadvantages of the Main Different A
Pancreatic Function Test Advantages
Fecal fat excretion/ Coefficient of
Fat Absorption
Clinically relevant
It detects other causes of maldige
Useful for monitoring response to




Theoretically it detects other caus
maldigestion
Probably useful for monitoring re
treatment
6 | www.annalsofsurgery.com13C-MTG might be more useful than the FE-1 for the diagnosis
of EPI after pancreatic surgery because of its higher accuracy, which
could be explained by the fact that fecal water content influences the
fecal enzyme concentration, resulting in falsely decreased FE-1
levels. The advantages and disadvantages of the different available
PFT are shown in Table 3.
To sum-up we need more studies to validate the use of FE-1
(which was associated with a poor correlation with FFE in two
studies and poor accuracy for the diagnosis of steatorrhea in one of
them) and 13C-MTG in surgical patients. In this scenario, the
diagnosis of EPI may be assumed in patients with symptoms
suggesting malabsortion. On the other hand, the absence of clinical
symptoms of steatorrhea is not an accurate method to exclude the
existence of EPI,2,12 and therefore PFT have a role in the diagnosis of
EPI in asymptomatic patients.
Question 8
When Should EPI Be Treated? Statement
Pancreatic enzyme replacement therapy should start once EPI
is diagnosed or when there is a high clinical suspicion of EPI.
Strength of the Recommendation and Quality of
Evidence: 2B Strong Agreement (A: 72.5%; B: 25%;
C: 2.5%)
Remarks. There is a paucity of high quality trials specifically
designed to assess when to treat EPI in patients with previous
pancreatic surgery. Most recommendations come from expert
opinion or guidelines from medical societies.9,47,95–98
The incidence of EPI associated with different surgical tech-
niques, its clinical consequences, and diagnosis have been addressed
in specific questions in this review. As a summary, deterioration of
pancreatic function frequently occurs after pancreatic surgery; this
condition is associated with relevant consequences. In patients with
pancreatic surgery and EPI, pancreatic enzyme replacement therapy
improves the CFA, the coefficient of nitrogen absorption, and
reduces flatulence, diarrhea, and abdominal pain,90,91,99,100 and
therefore EPI should be treated as soon as it is diagnosed. However,
the task of establishing the diagnosis of EPI in patients with previous
pancreatic surgery does not have a straightforward approach.51 To
overcome this limitation in patients with a high clinical suspicion of
EPI, its diagnosis may be accepted after an empiric therapeutic trial
showing that symptoms, nutritional markers or body weight improveauthorized reproduction of this article is prohibited.
after pancreatic enzyme replacement therapy.
vailable Pancreatic Function Tests
Disadvantages
Very cumbersome and difficult to perform
stion Not widely available
treatment
It does not detect other causes of maldigestion
Not useful for monitoring response to treatment
Low correlation with fecal fat excretion in operated
patients
es of Time-consuming
sponse to Not properly validated
Expensive
Scarcely available
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How Should EPI be Treated and How Should Follow-up
Be Performed?
Statement A. EPI after pancreatic surgery should be treated
with pancreatic enzyme replacement therapy with pancreatin in form
of enteric-coated minimicrospheres. Enzyme doses of 72,000–
75,000 Ph.U. of lipase with main meals and 36,000–50,000 Ph.U.
with snacks have shown to be effective in terms of improvement in
fat digestion.
Strength of the Recommendation and Quality of
Evidence: 1A. Strong Agreement (A: 70%; B: 27.5%; D:
2.5%)
Statement B. Follow up should be based on symptoms and
nutritional evaluation, including body weight and routine nutritional
parameters in blood.
Strength of the Recommendation and Quality of
Evidence: 2C. Strong Agreement (A: 70%; B: 27.5%; D:
2.5%)
Remarks. Treatment of EPI after any pancreatic surgical
procedure should be based on oral pancreatic enzyme replacement
therapy.91,99,101 Enzyme doses of 72,000–75,000 Ph.U. of lipase with
main meals and 36,000–50,000 Ph.U. with snacks have shown to be
effective in terms of improvement in fat digestion in RCTs.91,101 Only
two double-blind RCTs evaluating pancreatic enzyme replacement
therapy for EPI in patients after pancreatic surgery have been
reported.91,101 An open-label long-term follow-up study was
reported,99 with the patients from the double-blind study previously
published by Whitcomb et al91 In these two latter studies,91,99 results of
operated patients are reported together with nonoperated patients with
chronic pancreatitis, but the study from Seiler et al101 only addresses
operated patients, which also includes data from open-label pancreatic
enzyme replacement therapy administration for 1 year.
Compared with placebo, pancreatic enzyme replacement
therapy with pancreatin in form of enteric-coated minimicrospheres
is associated with a significant improvement of fat (CFA)91,101 and
protein digestion (coefficient of nitrogen absorption)101 in patients
after pancreatic resection for chronic pancreatitis or pancreatic
cancer. In addition, pancreatic enzyme replacement therapy is
associated with a significant weight gain and reduced stool fre-
quency.99,101
No study has been published which specifically focused on
dietary advice for patients after pancreatic surgery, it seems reason-
able that a normal healthy diet should be generally recommended
if tolerated.
No study has been found to answer the question about the follow
up of EPI in patients after pancreatic surgery. In our opinion, follow up
should be based on symptoms and nutritional evaluation, including
body weight and some routine nutritional parameters in blood (eg,
albumin, fat-soluble vitamins). Frequency of visits should be defined
depending on the clinical and nutritional status of patients. Once the
therapy has been optimized and the clinical and nutritional evaluation
is normal, further follow up should probably be on-demand.
Question 10
What Is the Quality of Life in Operated Patients With
EPI?
Statement. Exocrine pancreatic insufficiency is a relevant
prognostic factor related to impaired quality of life in patientsCopyright © 2016 Wolters Kluwer Health, Inc. U
who undergo pancreatic surgery.
 2016 Wolters Kluwer Health, Inc. All rights reserved.Strength of the Recommendation and Quality of
Evidence: 1B Strong Agreement (A: 72.5%; B: 25%; C:
2.5%)
Remarks. Quality of life deteriorates in patients who develop
EPI after pancreatic resection.101,102 In addition, the development of
postoperative EPI is a relevant prognostic factor, significantly affect-
ing the postoperative quality of life.41 Patients undergoing surgery
caused by pancreatic cancer with EPI score lower on quality of life
and functional scores.4 Long-term follow-up survivors are generally
satisfied with their quality of life, but bowel function, steatorrhea,
need for treatment of diarrhea, or need for pancreatic enzyme
replacement therapy and food intolerance may impair quality of
life.103–105 Patients with benign pancreatic tumors had higher quality
of life values at all time points compared with patients with pan-
creatitis and cancer; however, it is interesting to point out that quality
of life in this group did not reach normal values for the healthy
population even late after surgery, although these patients underwent
curative therapy and did not suffer per se a chronic pancreatic
disease.41 This is probably because of a higher rate of postoperative
EPI.41,106 Total pancreatectomy (TP) has a deep influence on short-
and long-term changes in the quality of life and EPI appears to be an
important factor41,107 because it especially affects symptom
scales.108 In acute pancreatitis, patients with long-term survival after
surgical treatment for infected pancreatic necrosis have a quality of life
comparable with that of the normal population.17 In patients with
chronic pancreatitis requiring surgery, quality of life improves sig-
nificantly both in the short and long term.41 Although the number of
patients with exocrine insufficiency is very high in CP, in some studies
such complication does not seem to have relevance in the overall
reported quality of life.23,28,109 Finally, in operated patients, regardless
of the disease requiring pancreatic resection, the type of reconstruction
technique does not affect their well being,110 and also among different
types of pancreatic head resection, the majority of functional and
symptom scales revealed a better quality of life and less steatorrhea in
duodenum-preserving pancreatic head resection.36,111
CONCLUSIONS
Pancreatic surgery is still a great challenge as it is frequently
associated with immediate surgical complications and long-term
sequelae. EPI is a frequent but under-recognized and under-treated
complication of pancreatic surgery. The lack of awareness and
information regarding the frequency, diagnostic methods, and recom-
mended therapy prompted the Spanish Association of Pancreatology
to design the present systematic review. EPI is commonly observed
after pancreatic surgery, it is clinically relevant and affects quality of
life; thus, it should be investigated, treated, and followed-up appro-
priately. The most important limitation of the literature and the origin
of much of the confusion on this topic is that the diagnosis of EPI
depends on the definition and the method used for measuring EPI and
there is a lack of studies trying to validate PFT with a proper gold
standard in operated patients. Therefore, further research is needed to
look for better and simpler diagnostic tools.
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